Equities Analysts Issue Forecasts for BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($4.24) per share for the year. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.05) per share.

A number of other research firms have also recently issued reports on BCYC. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. JMP Securities dropped their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research note on Wednesday, December 18th. B. Riley reduced their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Finally, Stephens restated an "equal weight" rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Bicycle Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $33.25.

Bicycle Therapeutics Stock Up 0.2 %

Shares of BCYC traded up $0.03 during mid-day trading on Thursday, hitting $13.23. 215,652 shares of the company traded hands, compared to its average volume of 335,918. The company has a market capitalization of $913.53 million, a PE ratio of -4.02 and a beta of 0.92. The business has a 50 day moving average of $16.92 and a 200 day moving average of $21.34. Bicycle Therapeutics has a 1-year low of $12.17 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the prior year, the business posted ($1.26) EPS. The business's revenue for the quarter was down 50.0% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. boosted its stake in Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company's stock worth $20,362,000 after purchasing an additional 841,299 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Bicycle Therapeutics during the second quarter worth about $11,577,000. Principal Financial Group Inc. acquired a new position in Bicycle Therapeutics during the third quarter worth about $10,028,000. Westfield Capital Management Co. LP grew its stake in Bicycle Therapeutics by 21.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock valued at $41,887,000 after acquiring an additional 327,089 shares in the last quarter. Finally, Armistice Capital LLC raised its holdings in Bicycle Therapeutics by 17.9% in the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company's stock valued at $39,913,000 after acquiring an additional 300,000 shares during the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker acquired 985,397 shares of the firm's stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the acquisition, the director now directly owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the sale, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,933 shares of company stock worth $549,501. Company insiders own 8.50% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.